Citi analyst David Lebowitz maintains $Intellia Therapeutics (NTLA.US)$ with a hold rating, and adjusts the target price from $29 to $19.
According to TipRanks data, the analyst has a success rate of 51.0% and a total average return of 1.4% over the past year.
Furthermore, according to the comprehensive report, the opinions of $Intellia Therapeutics (NTLA.US)$'s main analysts recently are as follows:
The detailed data presented from the Phase 2 study of NTLA-2002 versus placebo in hereditary angioedema, or HAE, suggests gene editing could potentially offer a one-time 'functional cure.' However, the irreversible nature of gene editing sets a high threshold for market acceptance, given the unknown long-term safety implications of this method. It remains uncertain whether NTLA-2002's efficacy stands out compared to currently available treatments.
Recent updates on Intellia Therapeutics' NTLA-2002 Phase 2 data indicated a reduction in attacks, which seemed less impressive when compared to the initial Phase 1 results for HAE presented in June at EAACI. Despite the attack reduction being within a range that rivals that of competitors' Phase 3 trials, the distinctive 'one-and-done' treatment approach of NTLA-2002 is highlighted as an advantage over other treatments that require more frequent dosing. There remains a competitive market opportunity for NTLA-2002, although expectations for its peak market share have been moderated, along with a more cautious perspective on the probability of success for NTLA-2001 in ATTR, noting that additional validation of the platform is necessary.
The perspective on Intellia Therapeutics has become incrementally negative after the results of the Phase 2 study of NTLA-2002 in patients with hereditary angioedema (HAE).
Note:
TipRanks, an independent third party, provides analysis data from financial analysts and calculates the Average Returns and Success Rates of the analysts' recommendations. The information presented is not an investment recommendation and is intended for informational purposes only.
Success rate is the number of the analyst's successful ratings, divided by his/her total number of ratings over the past year. A successful rating is one based on if TipRanks' virtual portfolio earned a positive return from the stock. Total average return is the average rate of return that the TipRanks' virtual portfolio has earned over the past year. These portfolios are established based on the analyst's preliminary rating and are adjusted according to the changes in the rating.
TipRanks provides a ranking of each analyst up to 5 stars, which is representative of all recommendations from the analyst. An analyst's past performance is evaluated on a scale of 1 to 5 stars, with more stars indicating better performance. The star level is determined by his/her total success rate and average return.
